Chromosomal aberrations induced by imipramine and desipramine in mouse

Abstract

Imipramine (IMI) and desipramine (DES) are two drugs widely used for the treatment of depression as well as for other diseases. In the present study, we determined their capacity to induce chromosomal aberrations in mouse bone marrow cells. Three doses of each compound were tested and their results were compared with the frequency of chromosomal aberrations obtained in a control group as well as with a group treated with cyclophosphamide. Our results showed a significant increase in chromosome damage with the doses tested for each compound: 7, 20, and 60 mg/kg in the case of IMI, and 2, 20, and 60 mg/kg as regards DES. This last drug induced stronger chromosomal damage than IMI. Our results agree with previous studies regarding the induction of micronuclei and sister chromatid exchanges by the drugs in mouse and suggest caution with respect to their use in long-term treatments.

Keywords

imipramine desipramine chromosomes mouse

References

Cruz-Vera M. , Lucena R. , Cardenas S. Fast urinary screening for imipramine and desipramine using on-line solid-phase extraction and selective derivatization. J Chromatogr B Biomed Sci Appl 2007; 857: 275-280.

Hultén BA , Heath A. Clinical aspects of tricyclic antidepressant poisoning. Acta Medica Scandinavica 1983; 213: 275-278.

Wise T. , Fishbain DA , Holder-Perkins V. Painful physical symptoms in depression: a clinical challenge. Pain Med 2007; 8: S75-S82.

Nalecz-Jawecki G. In vitro biotransformation of amitriptyline and imipramine with rat hepatic S9 fraction: evaluation of the toxicity with Spirotox and Thamnotoxkit FTM Tests. Arch Environ Contamin Toxicol 2008; 54: 266-273.

Amsterdam J. , Mendeis J. The clinical application of tricyclic antidepressant pharmacokinetics and plasma levels. Am J Psychiatr 1980; 137: 653-662.

Prichard DC , Greenberg DA Tricyclic antidepressants: therapeutic properties and affinity for alpha noradrenergic receptor binding. Science 1988; 199: 187-198.

Balbi A. , et al. Psychotropic drugs: evaluation of mutagenic effect. Pharmacol Res Commun 1980; 12: 423-431.

Fu TK , Jarvik LF In vitro effects of imipramine on human chromosomes. Mutat Res 1977; 48: 89-94.

Bishun N. , Smith N. , Williams DC Lack of in vivo cytogenetic action of imipramine in rats. Teratology 1974; 10: 191-192.

10.

Saxena R. , Ahuja YR Genotoxicity evaluation of the tricyclic antidepressants amitriptyline and imipramine using human lymphocyte cultures. Environ Mol Mutagen 1988; 12: 421-430.

11.

van Shaik N. , Graf U. Genotoxicity evaluation of five tricyclic antidepressants in the wing somatic mutation and recombination test of Drosophila melanogaster. Mutat Res 1991; 260: 99-104.

12.

Dündaröz R. , et al. DNA damage in children treated with imipramine for primary nocturnal enuresis. Pediatr Int 2002; 44: 617-621.

13.

Paniagua-Pérez R. , et al. Sister chromatid exchanges produced by imipramine and desipramine in mouse bone marrow cells treated in vivo. Toxicol Lett 2002; 132: 123-129.

14.

Madrigal-Bujaidar E. , et al. Micronuclei induced by imipramine and desipramine in mice: a subchronic study. Basic Clin Pharmacol Toxicol 2008; 103: 569-573.

15.

Madrigal-Santillán E. , et al. Inhibitory effect of mannan on the toxicity produced in mice fed aflatoxin B1 contaminated corn. Arch Environ Contamin Toxicol 2007; 53: 466-472.

16.

Gisselsson D. Classification of chromosome segregation errors in cancer. Chromosoma 2008; 117: 511-519.

17.

Geigl JB , Obenauf AC , Schwarztbraun T. , Speicher MR Defining ‘chromosomal instability’. Trends Genet 2008; 24: 64-69.

18.

Baird DM Mechanisms of telomeric instability. Cytogen Genome Res 2008; 122: 308-314.

19.

Birkebaek NH , Perrild BD Pheochromocytoma diagnosed in an enuretic boy after imipramine-induced hypertension. Pediatr Hematol Oncol 1986; 3: 283-285.

20.

Dublin S. , et al. Risk of epithelial ovarian cancer in relation to use of antidepressants, benzodiazepines, and other centrally acting medications. Canc Causes Contr 2002; 13: 35-45.

21.

Sharpe CR , Collet JP , Belzile E. , Hanley JA , Boivin JF The effect of tricyclic antidepressants on breast cancer risk. Br J Cancer 2002; 86: 92-97.

22.

Tamin HM , Mahmud S. , Hanley JA , Boivin JF , Stang MR , Collet JP Antidepressants and the risk of prostate cancer: a nested case-control. Prostate Cancer Prostatic Dis 2008; 11: 53-60.

23.

Sternbach H. Are antidepressants carcinogenic? A review of preclinical and clinical studies. J Clin Psychiatr 2003; 64: 1153-1162.

24.

Ziebarh D. , Schramm T. Effect of nontoxic inhibitors on the nitrosation of drugs under conditions simulating the human stomach. Archiv für Geschwulstforsch 1985; 55: 81-91.

25.

Brambilla G. , Martelli A. Genotoxic and carcinogenic risk to humans of drug-nitrite interaction products. Mutat Res 2007; 635: 17-52.

26.

De Vane CL , Simpkins JW Pharmacokinetics of imipramine and its major metabolites in pregnant rats and their fetuses following a single dose. Drug Metabol Dispos 1985; 13: 438-442.

27.

Bílá V. , Kren V. Teratogenicity testing based on the interaction with a mutant allele. Folia Biol (Praha ) 1992; 38: 40-47.

28.

Bournias-Vardabasis N. , Teplitz RL , Chernoff GF , Seecof RL Detection of teratogens in the Drosophila embryonic cell culture test: assay of 100 chemicals. Teratology 1983; 28: 109-122.

29.

Arimochi H. , Morita K. Characterization of cytotoxic actions of tricyclic antidepressants in human HT29 colon carcinoma cells. Eur J Pharmacol 2006; 541: 17-23.

30.

Hernandez D. , et al. Deletion of the mouse Fmo1 gene results in enhanced pharmacological behavioural responses to imipramine. Pharmacogenet Genomics 2009; 19: 289-299.

31.

Brüss M. , Kunz J. , Lingen B. , Bönisch H. Chromosomal mapping of the human gene for the tricyclic antidepressant-sensitive noradrenaline transporter. Human Genet 1993; 91: 278-280.

32.

Barker EL , Blakely RD Identification of a single amino acid, phenylalanine 586, that is responsible for the high affinity interactions of tricyclic antidepressants with the human serotonin transporter. Mol Pharmacol 1991; 50: 957-965.

33.

Xia Z. , et al. Changes in the generation of reactive oxygen species and in mitochondrial membrane potential during apoptosis induced by the antidepressants imipramine, clomipramine, and citalopram and the effects on these changes by Bcl-2 and Bcl-X (L). Biochem Pharmacol 1999; 57: 1199-1208.

34.

Slamon LD , Ward TH , Butler J. , Pentreath VW Assessment of DNA damage in C6 glioma cells after antidepressant treatment using an alkaline comet assay. Arch Toxicol 2001; 75: 243-250.

35.

Isobe T. , et al. Different effects of desipramine on bufuralol I’-hidroxylation by rat human CYP2D enzymes. Biol Pharmaceut Bull 2005; 28: 634-640.

36.

Masabuchi N. , Makino C. , Murayama N. Prediction of in vivo potential for metabolic activation of drugs into chemically reactive intermediate: correlation of in vitro and in vivo generation of reactive intermediates and in vitro glutathione conjugate formation in rats and humans. Chem Res Toxicol 2007; 20: 455-464.